Scancell Holdings plc(SCP)

Description: Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

---

Keywords: Cancer Solid Tumors Infectious Diseases Treatment Of Cancer Immunotherapy Vaccines Non Small Cell Lung Cancer Immunotherapies Pancreatic Cancer Melanoma Virotherapy Cancer Vaccine Metastatic Melanoma Treatment Of Metastatic Melanoma Gritstone Bio Scib1 Modi

---

Home Page: www.scancell.co.uk

Bellhouse Building
Oxford, OX4 4GD
United Kingdom
Phone: 44 18 6558 2066

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)